A First In Human Randomised, Double-Blind, Placebo-Controlled Study Of Single Ascending Doses In Healthy Male Volunteers And Repeated Ascending Dose In Asthmatic Patients Followed By A 3-Way Cross-Over, Placebo-Controlled, Single-Dose In Copd Patients To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CHF6366

Trial Profile

A First In Human Randomised, Double-Blind, Placebo-Controlled Study Of Single Ascending Doses In Healthy Male Volunteers And Repeated Ascending Dose In Asthmatic Patients Followed By A 3-Way Cross-Over, Placebo-Controlled, Single-Dose In Copd Patients To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CHF6366

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs CHF-6366 (Primary) ; Umeclidinium; Vilanterol
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Adverse reactions; First in man
  • Sponsors Chiesi Farmaceutici SpA
  • Most Recent Events

    • 03 Jan 2018 Planned End Date changed from 20 Jul 2019 to 28 Aug 2018.
    • 03 Jan 2018 Planned primary completion date changed from 20 Jul 2019 to 28 Aug 2018.
    • 03 Jan 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top